Atea Pharmaceuticals, Inc. (AVIR): who owns it and who trades it
As of Nov 16, 2026, AVIR insiders reported 1 purchase worth $25.4K in the last 12 months. The largest buyer was Polly A. Murphy (Director), with $25.4K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Atea Pharmaceuticals
From the latest filingsOverall: about as much buying as selling. Famous investors mostly sold. Insiders mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns AVIR
124 funds and institutions reported AVIR shares worth $279M at the end of Q2 2026, about 75% of the company. The largest holder is FMR LLC (Fidelity) with 15.1%.
Funds and institutions (13F) 75%Everyone else 25%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 12.00M | 15.07% | $55.8M | +0% |
| BlackRock, Inc. | 8.72M | 10.94% | $40.5M | +3% |
| BML Capital Management, LLC | 6.95M | 8.73% | $32.3M | -2% |
| Tang Capital Management LLC | 4.81M | 6.04% | $22.4M | No change |
| Vanguard Capital Management LLC | 2.96M | 3.72% | $13.8M | -9% |
| Bain Capital Life Sciences Investors, LLC | 2.08M | 2.61% | $9.7M | -12% |
| Acadian Asset Management LLC | 2.04M | 2.55% | $9.5M | +29% |
| Geode Capital Management, LLC | 1.96M | 2.46% | $9.1M | +12% |
| State Street Corp | 1.65M | 2.07% | $7.7M | -2% |
| Two Sigma Investments, LP | 1.51M | 1.89% | $7M | -19% |
| Dimensional Fund Advisors LP | 1.30M | 1.63% | $6M | +4% |
| Renaissance Technologies LLC | 1.13M | 1.42% | $5.3M | -3% |
| Rosalind Advisors, Inc. | 1.07M | 1.34% | $5M | -9% |
| JPMorgan Chase & Co | 945,918 | 1.19% | $4.4M | – |
| Northern Trust Corp | 755,239 | 0.95% | $3.5M | +29% |
| Morgan Stanley | 719,514 | 0.90% | $3.3M | -2% |
| Vanguard Portfolio Management LLC | 630,185 | 0.79% | $2.9M | +13% |
| Charles Schwab Investment Management Inc | 610,607 | 0.77% | $2.8M | +2% |
| Sixth Street Partners Management Company, L.P. | 610,607 | 0.77% | $2.8M | – |
| Goldman Sachs Group Inc | 530,856 | 0.67% | $2.5M | -10% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, AVIR insiders reported $25.4K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | Polly A. Murphy | Director | Purchase | 6,100 | $4.17 | $25.4K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Polly A. Murphy | Director | $25.4K | – | May 18, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AVIR short interest
Low short interest. 3.8% of AVIR shares are sold short: about 1 share in 27. Over the last 12 reports the number of shares short went down 60%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.01M AVIR shares were sold short, 3.8% of the shares outstanding, down 2.0% from the report before. At the average daily volume of 315,089 shares, buying them all back would take about 9.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.01M | 3.75% | -2% | 315,089 | 9.6 |
| Oct 15, 2026 | 3.07M | 3.83% | -61% | 287,224 | 10.7 |
| Sep 30, 2026 | 7.89M | 9.83% | +3% | 304,918 | 25.9 |
| Sep 15, 2026 | 7.63M | 9.51% | -0% | 279,462 | 27.3 |
| Aug 31, 2026 | 7.66M | 9.56% | -0% | 186,207 | 41.2 |
| Aug 14, 2026 | 7.67M | 9.56% | +2% | 288,345 | 26.6 |
| Jul 31, 2026 | 7.53M | 9.45% | -3% | 417,474 | 18.0 |
| Jul 15, 2026 | 7.76M | 9.74% | +11% | 340,925 | 22.8 |
| Jun 30, 2026 | 6.99M | 8.77% | -1% | 435,957 | 16.0 |
| Jun 15, 2026 | 7.07M | 8.88% | -6% | 244,779 | 28.9 |
| May 29, 2026 | 7.53M | 9.45% | -1% | 314,525 | 23.9 |
| May 15, 2026 | 7.59M | 9.53% | +1% | 384,814 | 19.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Atea Pharmaceuticals company events
Atea Pharmaceuticals filed 7 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Nov 9, 2026AgreementAtea Pharmaceuticals, Inc. entered into a Loan and Security Agreement with Hercules Capital, Inc., as agent, and the lenders party thereto, providing for term loans in an of up to $200.0 million, subject to the terms and conditions set forth therein. Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jun 22, 2026VoteReported shareholder vote results. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Mar 5, 2026ResultsReleased financial results. Filing
- Jan 8, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Atea Pharmaceuticals financials
Famous investors that hold AVIR
3 of the 50 well-known investors we track reported holding AVIR in their latest 13F filing. The largest position is Jim Simons's, worth $5.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.09M | $5.7M | 0.0% | -3% |
| Israel Englander · Millennium Management | Q3 2026 | 159,884 | $833K | 0.0% | -48% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 14,850 | $77.4K | 0.0% | -91% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named AVIR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | JPM Partners LLC | 13G/A | 6.4% |
| Nov 13, 2026 | JPM Partners LLC | 13G/A | 6.4% |
| Oct 6, 2026 | TANG CAPITAL MANAGEMENT, LLC | 13G | 6.0% |
| Oct 6, 2026 | TANG CAPITAL MANAGEMENT, LLC | 13G | 6.0% |
Questions about Atea Pharmaceuticals, Inc. (AVIR) stock
Who owns the most AVIR stock?
The largest reported owner of Atea Pharmaceuticals, Inc. (AVIR) is FMR LLC (Fidelity), with 15.1% of the company. In total, 124 funds and institutions reported holding AVIR at the end of Q2 2026, together about 75% of the shares. See the largest owners.
Are AVIR insiders buying or selling?
In the last 12 months, AVIR insiders reported 1 open-market purchase worth $25.4K and no sales. The latest trade was on May 18, 2026. See every trade.
What is the short interest in AVIR?
As of Oct 30, 2026, 3.01M AVIR shares were sold short, 3.8% of the shares outstanding, down 2.0% from the report before. At the average daily volume of 315,089 shares, buying them all back would take about 9.6 trading days (days to cover). See the history.
Which famous investors hold AVIR?
3 of the 50 well-known investors we track reported AVIR in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $5.7M. See all holders.
Executive pay
Atea Pharmaceuticals's chief executive was paid a total of $3.4M for the year ended Dec 31, 2025, down 19% from $4.2M the year before. In the last 12 months, Atea Pharmaceuticals's executives and directors bought $50.9K of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.